$TPST
Tempest Therapeutics, Inc.

2024 Q1 Form 10-K Financial Statement

#000095017024033555 Filed on March 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.634M $3.331M $11.66M
YoY Change 25.18% 6.08% -3.75%
% of Gross Profit
Research & Development $4.340M $4.183M $17.50M
YoY Change -7.23% -27.8% -22.32%
% of Gross Profit
Depreciation & Amortization $88.00K $85.00K $381.0K
YoY Change -29.6% -60.83% -40.28%
% of Gross Profit
Operating Expenses $4.340M $7.514M $29.16M
YoY Change -7.23% -15.89% 29.43%
Operating Profit -$7.974M -$29.16M
YoY Change 5.18% -15.83%
Interest Expense $368.0K $26.00K -$334.0K
YoY Change 6.98% -106.02% -120.64%
% of Operating Profit
Other Income/Expense, Net $70.00K -$334.0K
YoY Change -227.27% -68.76%
Pretax Income -$7.904M -$7.488M -$29.49M
YoY Change 3.51% -17.74% -17.41%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.904M -$7.488M -$29.49M
YoY Change 3.51% -17.74% -17.41%
Net Earnings / Revenue
Basic Earnings Per Share -$0.36 -$1.91
Diluted Earnings Per Share -$0.36 -$0.38 -$1.91
COMMON SHARES
Basic Shares Outstanding 22.19M 19.25M 15.42M
Diluted Shares Outstanding 22.23M 15.42M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.33M $39.23M $39.23M
YoY Change 41.01% 25.62% 25.62%
Cash & Equivalents $32.30M $39.23M $39.23M
Short-Term Investments
Other Short-Term Assets $469.0K $1.133M $1.133M
YoY Change 11.93% 330.8% -34.13%
Inventory
Prepaid Expenses $585.0K $700.0K
Receivables
Other Receivables
Total Short-Term Assets $33.50M $40.36M $40.36M
YoY Change 35.76% 22.5% 22.5%
LONG-TERM ASSETS
Property, Plant & Equipment $920.0K $10.79M $10.79M
YoY Change -8.73% 918.11% -15.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $448.0K $448.0K $448.0K
YoY Change 4.43% 4.43% 4.43%
Total Long-Term Assets $10.88M $11.24M $11.24M
YoY Change -14.02% -14.45% -14.45%
TOTAL ASSETS
Total Short-Term Assets $33.50M $40.36M $40.36M
Total Long-Term Assets $10.88M $11.24M $11.24M
Total Assets $44.38M $51.60M $51.60M
YoY Change 18.88% 11.96% 11.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.051M $845.0K $845.0K
YoY Change -9.16% -23.74% -23.74%
Accrued Expenses $1.524M $4.281M $4.281M
YoY Change -39.95% 44.58% -25.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $6.458M $4.285M $4.285M
YoY Change 336.06%
Total Short-Term Liabilities $10.69M $9.411M $9.411M
YoY Change 42.34% 29.33% 29.33%
LONG-TERM LIABILITIES
Long-Term Debt $4.140M $6.264M $6.264M
YoY Change -53.67% -39.6% -39.6%
Other Long-Term Liabilities $8.915M $9.160M $9.160M
YoY Change -10.11% -11.33% -11.33%
Total Long-Term Liabilities $4.140M $15.42M $15.42M
YoY Change -53.67% 48.72% -25.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.69M $9.411M $9.411M
Total Long-Term Liabilities $4.140M $15.42M $15.42M
Total Liabilities $23.75M $24.84M $24.84M
YoY Change -9.93% -11.23% -11.23%
SHAREHOLDERS EQUITY
Retained Earnings -$173.2M -$165.3M
YoY Change 20.75% 21.72%
Common Stock $22.00K $22.00K
YoY Change 100.0% 100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $20.63M $26.77M $26.77M
YoY Change
Total Liabilities & Shareholders Equity $44.38M $51.60M $51.60M
YoY Change 18.88% 11.96% 11.96%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$7.904M -$7.488M -$29.49M
YoY Change 3.51% -17.74% -17.41%
Depreciation, Depletion And Amortization $88.00K $85.00K $381.0K
YoY Change -29.6% -60.83% -40.28%
Cash From Operating Activities -$7.186M -$6.175M -$27.36M
YoY Change -13.45% -4.69% -11.96%
INVESTING ACTIVITIES
Capital Expenditures $168.0K $7.000K $170.0K
YoY Change 265.22% -98.03% -69.75%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$168.0K -$7.000K -$170.0K
YoY Change 265.22% -98.03% -69.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $35.60M
YoY Change 301.78%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 450.0K 34.35M 35.60M
YoY Change 922.73% -826.81% 212.22%
NET CHANGE
Cash From Operating Activities -7.186M -6.175M -27.36M
Cash From Investing Activities -168.0K -7.000K -170.0K
Cash From Financing Activities 450.0K 34.35M 35.60M
Net Change In Cash -6.904M 28.17M 8.075M
YoY Change -16.87% -343.64% -139.91%
FREE CASH FLOW
Cash From Operating Activities -$7.186M -$6.175M -$27.36M
Capital Expenditures $168.0K $7.000K $170.0K
Free Cash Flow -$7.354M -$6.182M -$27.53M
YoY Change -11.92% -9.55% -12.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001544227
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration
PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
http://fasb.org/us-gaap/2023#LeaseholdImprovementsMember
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-35890
CY2023 dei Entity Registrant Name
EntityRegistrantName
Tempest Therapeutics, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-1472564
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2000 Sierra Point Parkway
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Brisbane
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94005
CY2023 dei City Area Code
CityAreaCode
(415)
CY2023 dei Local Phone Number
LocalPhoneNumber
798-8589
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
16000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22192026
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10518539
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10518539
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Chicago, Illinois
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39230000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31230000
CY2022Q4 us-gaap Insurance Settlements Receivable
InsuranceSettlementsReceivable
450000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1133000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
40363000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
32950000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
840000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9952000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11650000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
448000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
429000
CY2023Q4 us-gaap Assets
Assets
51603000
CY2022Q4 us-gaap Assets
Assets
46089000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
845000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1108000
CY2022Q4 us-gaap Litigation Reserve Current
LitigationReserveCurrent
450000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1673000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2961000
CY2023Q4 us-gaap Deferred Finance Costs Current Net
DeferredFinanceCostsCurrentNet
112000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4285000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
952000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1413000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1543000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1248000
CY2023Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
113000
CY2022Q4 us-gaap Interest And Dividends Payable Current
InterestAndDividendsPayableCurrent
97000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9411000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7277000
CY2023Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
164000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
454000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6264000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
10371000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9160000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10330000
CY2023Q4 us-gaap Liabilities
Liabilities
24835000
CY2022Q4 us-gaap Liabilities
Liabilities
27978000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22045255
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22045255
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
192009000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
153872000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-165263000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-135772000
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26768000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
18111000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51603000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46089000
CY2023 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
17498000
CY2022 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
22527000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11659000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12113000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-29157000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-34640000
CY2023 us-gaap Interest Expense
InterestExpense
1449000
CY2022 us-gaap Interest Expense
InterestExpense
1618000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1115000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
549000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-334000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1069000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Profit Loss
ProfitLoss
-29491000
CY2022 us-gaap Profit Loss
ProfitLoss
-35709000
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.09
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15416203
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15416203
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11548907
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11548907
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
36117000
CY2022 tpst Stock Issuance Costs
StockIssuanceCosts
489000
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8861000
CY2022 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1561000
CY2022 tpst Warrant Issuance Costs
WarrantIssuanceCosts
283000
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7281000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35709000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18111000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2023 tpst Stock Issuance Costs
StockIssuanceCosts
1105000
CY2023 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35598000
CY2023 tpst Exercise Of Pre Funded Warrants
ExerciseOfPreFundedWarrants
3000
CY2023 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2546000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29491000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26768000
CY2023 us-gaap Profit Loss
ProfitLoss
-29491000
CY2022 us-gaap Profit Loss
ProfitLoss
-35709000
CY2023 us-gaap Depreciation
Depreciation
381000
CY2022 us-gaap Depreciation
Depreciation
638000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2546000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1561000
CY2023 tpst Noncash Lease Expense
NoncashLeaseExpense
1698000
CY2022 tpst Noncash Lease Expense
NoncashLeaseExpense
1176000
CY2023 tpst Noncash Interest And Other Expense Net
NoncashInterestAndOtherExpenseNet
186000
CY2022 tpst Noncash Interest And Other Expense Net
NoncashInterestAndOtherExpenseNet
394000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-193000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-915000
CY2023 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-263000
CY2022 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-992000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
1709000
CY2023 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
16000
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-256000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1631000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1501000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27357000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31072000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
562000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-170000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-562000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35602000
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8861000
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
7281000
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
4739000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
35602000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11403000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8075000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-20231000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31598000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51829000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39673000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31598000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
1249000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
1539000
CY2023 tpst Corporatetaxespaid
Corporatetaxespaid
191000
CY2022 tpst Corporatetaxespaid
Corporatetaxespaid
18000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
10660000
CY2022 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
884000
CY2023 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
0
CY2022 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
93000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39200000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development accruals, recoverability of long-lived assets, right-of-use assets, lease obligations, stock-based compensation and income taxes uncertainties and valuation allowances. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from those estimates.</span></p>
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—Financial instruments, which potentially subject the Company to concentration of risk, consist principally of cash and money market fund. All of the Company’s cash and money market fund are deposited in accounts with a major financial institution in excess of federally insured limits. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents to the extent recorded in the balance sheets. While the Company has not experienced any losses in such accounts, the recent failure of Silicon Valley Bank (SVB), at which the Company held cash and cash equivalents in multiple accounts, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company had subsequently transferred its accounts to one or more alternate depository institutions. The Company has no off-balance sheet concentrations of credit risk, such as foreign currency exchange contracts, option contracts or other hedging arrangements.</span></p>
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
700000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
703000
CY2023Q4 tpst Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
337000
CY2022Q4 tpst Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
304000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
96000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
263000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1133000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1270000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1865000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2421000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1025000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1361000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
840000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1060000
CY2023 us-gaap Depreciation
Depreciation
381000
CY2022 us-gaap Depreciation
Depreciation
638000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
626000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
756000
CY2023Q4 tpst Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
1047000
CY2022Q4 tpst Accrued Clinical Trial Liability
AccruedClinicalTrialLiability
2205000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1673000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2961000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
10500000
CY2021Q2 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5365899
CY2021Q2 tpst Stockholders Equity Note Stock Split Exchange Ratio
StockholdersEquityNoteStockSplitExchangeRatio
0.0322
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22045255
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22045255
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10518539
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10518539
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2023 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
1.10
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
790637
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
32.82
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
909527
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.34
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
147123
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
128.79
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1553041
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.66
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2308800
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.26
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
713
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.23
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
307016
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.97
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3554112
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.28
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3554112
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M14D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.28
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2737358000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3554112
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y9M14D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
7.28
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2737358000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1041752
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y5M1D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.52
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
906002000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2546000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1561000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-6192000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-7497000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2492000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2733000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
9129000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8581000
CY2023 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
836000
CY2022 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1173000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
371000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2606000
CY2023 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
20000
CY2022 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
216000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
136901000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
131346000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
19240000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
18122000
CY2023Q4 tpst Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Amortization
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization
730000
CY2022Q4 tpst Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Amortization
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAmortization
916000
CY2023Q4 tpst Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
3018000
CY2022Q4 tpst Deferred Tax Assets Operating Lease Liability
DeferredTaxAssetsOperatingLeaseLiability
3504000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
809000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
576000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
449000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
378000
CY2023Q4 tpst Deferred Tax Assets Capital Research And Development
DeferredTaxAssetsCapitalResearchAndDevelopment
6466000
CY2022Q4 tpst Deferred Tax Assets Capital Research And Development
DeferredTaxAssetsCapitalResearchAndDevelopment
4138000
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
0
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
10000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
167613000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
158990000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
164643000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
155514000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2970000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3476000
CY2023Q4 tpst Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
2970000
CY2022Q4 tpst Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
3476000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2970000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3476000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9100000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
482100000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
457800000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
466000000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
434400000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4650000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4293000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
273000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
357000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4923000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4650000
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
147000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
126000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-29491000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-35709000
CY2023 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
15416203
CY2022 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
11548907
CY2023 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2022 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15416203
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15416203
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11548907
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11548907
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.91
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.91
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.09
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3685148
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1559077
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-033555-index-headers.html Edgar Link pending
0000950170-24-033555-index.html Edgar Link pending
0000950170-24-033555.txt Edgar Link pending
0000950170-24-033555-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img41960366_0.jpg Edgar Link pending
img41960366_1.jpg Edgar Link pending
img41960366_2.jpg Edgar Link pending
img41960366_3.jpg Edgar Link pending
img41960366_4.jpg Edgar Link pending
img41960366_5.jpg Edgar Link pending
img41960366_6.jpg Edgar Link pending
img41960366_7.jpg Edgar Link pending
img41960366_8.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tpst-20231231.htm Edgar Link pending
tpst-20231231.xsd Edgar Link pending
tpst-ex10_26.htm Edgar Link pending
tpst-ex23_1.htm Edgar Link pending
tpst-ex31_1.htm Edgar Link pending
tpst-ex31_2.htm Edgar Link pending
tpst-ex32_1.htm Edgar Link pending
tpst-ex4_1.htm Edgar Link pending
tpst-ex97_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
tpst-20231231_htm.xml Edgar Link completed